Effects of Sarcomere Activators and Inhibitors Targeting Myosin Cross-Bridges on Ca^{2+} -Activation of Mature and Immature Mouse Cardiac Myofilaments

Monika Halas*, Paulina Langa*, Chad M. Warren, Paul H. Goldspink, Beata M. Wolska, R. John Solaro

Department of Physiology and Biophysics and the Center for Cardiovascular Research, College of Medicine, University of Illinois at Chicago, Chicago, IL. (M.H., P.L., C.M.W., P.H.G., B.M.W., R.J.S.)

Department of Medicine, Division of Cardiology, University of Illinois at Chicago, Chicago, IL. (B.M.W.)

* These authors made equal contributions to this manuscript

R. John Solaro's laboratory was the primary origin of the presented study.

Running Title:

Myosin Activators and Inhibitors in Immature Cardiac Sarcomeres

Correspondence:

Paulina Langa, PhD

Department of Physiology and Biophysics (M/C 901)

University of Illinois at Chicago, College of Medicine

835 South Wolcott Avenue

Chicago, IL 60612

planga2@uic.edu

Fax: 312-996-1414

Tel: 312-996-9176 (office), 312-687-8215 (mobile)

Total number of text pages 42

Total number of figures 8

Total number of tables 5

Total number of references 54

Total word count of the Abstract 249

Total word count of the Introduction 735

Total word count of the Discussion 1,381

Abbreviations: BES, (N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid); cMyBP-C, cardiac myosin binding protein C; cTnT, cardiac troponin T; DRX, disordered relaxed state; EGTA, ethylene glycol-bis(β -aminoethyl ether)-N,N,N',N'-tetraacetic acid); HCM, hypertrophic cardiomyopathy; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with restrictive ejection fraction; HR, high-relaxing buffered solution; K-Prop, potassium propionate; Mava, Mavacamten; μ M, micromolar; mM, millimolar; $MgCl_2$, magnesium dichloride; Na_2ATP , Adenosine 5'-triphosphate disodium salt hydrate; Na_2CrP , disodium creatine phosphate; NTG, non-transgenic; OM, Omecamtiv Mecarbil; pCa, ($-\log[Ca^{2+}]$); SDS-PAGE,

sodium dodecyl sulfate-polyacrylamide gel electrophoresis; SRX, super relaxed state; ssTnI, slow skeletal troponin I; TG, transgenic; WT, wildtype.

Abstract

We tested the hypothesis that isoform shifts in sarcomeres of the immature heart modify the effect of cardiac myosin-directed sarcomere inhibitors and activators. Omecamtiv mecarbil (OM) activates tension and is in clinical trials for the treatment of adult acute and chronic heart failure. Mavacamten (Mava) inhibits tension and is in clinical trials to relieve hyper-contraction and outflow obstruction in advanced genetic hypertrophic cardiomyopathy (HCM) linked commonly to mutations in sarcomeric proteins. To address the effect of these agents in developing sarcomeres we isolated heart fiber bundles, extracted membranes with Triton X-100, and measured tension developed over a range of Ca^{2+} concentrations with and without OM or Mava treatment. We made measurements in fiber bundles from hearts of adult non-transgenic controls (NTG) expressing cardiac troponin I (cTnI), and from hearts of transgenic mice (TG-ssTnI) expressing the fetal/neonatal form, slow skeletal troponin I (ssTnI). We also compared fibers from 7+14-day-old NTG mice expressing ssTnI and cTnI. These studies were repeated with 7+14-day old transgenic mice (TG-cTnT-R92Q) expressing a mutant form of cardiac TnT (cTnT) linked to HCM. OM increased Ca^{2+} -sensitivity and decreased cooperative activation in both ssTnI- and cTnI- regulated myofilaments with a similar effect reducing sub-maximal tension in immature and mature myofilaments. Although Mava decreased tension similarly in cTnI- and ssTnI-regulated myofilaments controlled either by cTnT or cTnT-R92Q, its effect involved a depressed Ca^{2+} -sensitivity in the mature cTnT-R92-myofilaments. Our data demonstrate an influence of myosin and thin filament-associated proteins on the actions of myosin-directed agents such as OM and Mava.

Significance Statement

The effects of myosin-targeted activators and inhibitors on Ca^{2+} -activated tension in developing cardiac sarcomeres presented here provide novel, *ex-vivo* evidence as to their actions in early-stage cardiac disorders. These studies advance understanding of the molecular mechanisms of

these agents that is important in pre-clinical studies employing sarcomere Ca^{2+} -response as a screening approach. The data also inform the use of commonly immature cardiac myocytes generated from human inducible pluripotent stem cells in screening for sarcomere activators and inhibitors.

Introduction

A recent advance in the treatment of adult cardiac disorders is the development of inotropic agents that are new classes of sarcomere activators and inhibitors in phase 3 clinical trials. The successful and safe use of these agents in adult hearts led to our hypothesis that they may also be effective in immature myofilaments of pediatric patients with heart failure and cardiomyopathies. The agents we employed in our studies of Ca^{2+} -activation of myofilament tension are omecamtiv mecarbil: $\text{C}_{20}\text{H}_{24}\text{FN}_5\text{O}_3$, methyl 4-(2-fluoro-3-(3-(6-Methylpyridin-3-yl)ureido)benzyl)piperazine-1-carboxylate (OM), a myosin targeted sarcomere activator (Teerlink et al., 2020; Teerlink et al., 2021) (Fig. 1A) and mavacamten: $\text{C}_{15}\text{H}_{19}\text{N}_3\text{O}_2$, (S)-3-Isopropyl-6-((1-phenylethyl)amino) pyrimidine-2,4(1H,3H)-dione (Mava), a myosin targeted sarcomere inhibitor (Toepfer et al., 2020; Zampieri et al., 2021) (Fig. 1B). OM was developed as an agent enhancing sarcomere response to Ca^{2+} without affecting myocyte Ca^{2+} fluxes (Malik et al., 2011; Planelles-Herrero et al., 2017). OM is currently in clinical trials testing its effects in heart failure patients with reduced ejection fraction (HFrEF) (Teerlink et al., 2021). Mava was developed as a sarcomere inhibitor for use in hypertrophic cardiomyopathy (HCM) with hypercontractility and outflow obstruction, which is often linked to sarcomere protein mutations. Mava is also in a clinical trial testing its effects in patients with HCM, a condition that may lead to heart failure with preserved ejection fraction (HFpEF) (Ho et al., 2020).

Cardiac contraction and relaxation are controlled by sarcomeres expressing different protein isoforms in mature and immature myofilaments. A dominant isoform switch occurs in cardiac troponin (Tn), a thin filament hetero-trimeric complex that together with tropomyosin (Tm) controls the Ca^{2+} -dependent reaction of thin filaments with force generating myosin cross-bridges (Solaro et al., 2013; Solis and Solaro, 2021). The mechanism of action for OM and Mava has been attributed to their modification of the state of myosin cross-bridges, effectively adding or removing the number of myosin heads that can participate in shortening and force

generation (Green et al., 2016; Teerlink et al., 2021). However, evidence exists that the mechanism may also involve other sarcomere proteins (Kampourakis et al., 2018; Mamidi et al., 2015), including those that shift isoforms in the immature heart. A major and substantial isoform shift is in the thin filament regulatory unit made up of 7 actins with one tropomyosin (Tm), and one Tn complex consisting of cardiac troponin C (cTnC), a Ca^{2+} -binding unit, TnI, an inhibitory unit, and TnT, a Tm-binding unit. Ca^{2+} binding to cTnC triggers contraction by releasing the actin-cross-bridge interaction from the combined inhibition of cTnI, cTnT and Tm. Promotion of actin-cross-bridge reactions also occurs in a highly cooperative process involving near-neighbor interactions of regulatory units. Although there are similar control mechanisms in immature and mature hearts, adult sarcomeres are controlled by an adult form, cardiac TnI (cTnI), whereas immature sarcomeres are controlled by a fetal/neonatal isoform, which is identical to the slow skeletal muscle isoform, ssTnI (Hunkeler et al., 1991; Murphy et al., 1991). The ssTnI isoform is expressed in fetal and neonatal hearts before a complete switch to the adult cTnI. In mouse hearts, the switch from ssTnI occurs incrementally with the expression of 100% cTnI by 10-14 days of age. Studies of expression of ssTnI in human hearts have demonstrated a similar pattern in developing and adult human hearts (Sasse et al., 1993).

Among the changes in the isoform population that occur in the fetal/neonatal heart, there is substantial evidence that the impact of ssTnI on the control of cardiac myofilaments is a dominant mechanism in developing hearts (Layland et al., 2005; Metzger et al., 2003). In addition to isoform distributions, molecular modifications in the primary structure of ssTnI also alter pH sensitivity, cooperative activation, and protein phosphorylation (Solaro et al., 2013). Cardiac muscle preparations with sarcomeres controlled by ssTnI vs. cTnI demonstrate altered responses to physiological controllers (Solaro et al., 2013), pathological stresses, and pharmacological interventions (Arteaga et al., 2000). These findings indicate a strong possibility

that inhibition or activation of sarcomeres by OM and Mava may be different in immature compared to adult sarcomeres.

We tested the effects of OM and Mava on myofilaments from adult and neonatal hearts expressing either cTnI, ssTnI together with wildtype cTnT, or a mutant cTnT linked to HCM. Our results revealed novel differential effects of the agents on Ca^{2+} -sensitivity and cooperative activation of tension in sarcomeres controlled by either cTnI or ssTnI. These results provide evidence relating to the effects of these sarcomere directed agents in early-stage cardiac disorders.

Methods

Mouse Models

Experiments were approved by the Animal Care and Use Committee of the University of Illinois at Chicago and in compliance with the Guide for the Care and Use of Laboratory Animals as adopted by the U.S. National Institutes of Health. One set of experiments employed male and female adult non-transgenic (NTG) or transgenic (TG) adult mice on an FVB/N background expressing ssTnI (TG-ssTnI) in the cardiac compartment, as previously described (Alves et al., 2017). A second set of experiments employed male and female 7- and 14-day old NTG mice and TG mice (TG-cTnT-R92Q) expressing an HCM-linked TnT mutant generated in C57/B6 strain as previously described (Chowdhury et al., 2020; Tardiff et al., 1999). Since it is well-known that genetic background may have a notable effect on the HCM phenotype (Michele et al., 2002; Prabhakar et al., 2001; Rowlands et al., 2017), we first rederived and characterized TnT-R92Q mice in FVB/N background to be consistent with TG-ssTnI mice. We crossed TnT-R92Q heterozygous male with FVB/N female to create F1 generation of mice. Next, we bred TnT-R92Q-positive male from F1 generation with FVB/N female to obtain F2 generation of mice. We repeated this process up to F10 generation.

Detergent-Extracted (Skinned) Bundles of Ventricular Muscle Fibers

In one set of experiments, we extracted hearts from 3-5-month-old NTG and TG-ssTnI mice that were heparinized and anesthetized with a ketamine/xylazine solution (200mg/20mg/kg body weight) in accord with the Veterinary Medical Association Panel on Euthanasia Guidelines. To prepare detergent-extracted fiber bundles, we carried out procedures essentially as previously described (Ryba et al., 2019). Following heart extraction, and exposure of the left ventricular papillary muscle, we dissected fiber bundles 3-5 mm in length and 150-200 μ m in diameter in a

high relaxing buffer (HR), pH 7.0 (10 mM EGTA, 41.89 mM K-Prop, 100 mM BES, 6.75 mM MgCl_2 , 6.22 mM Na_2ATP , 10 mM Na_2CrP , 5 mM NaN_3 , ionic strength 150 mM).

Use of sodium azide is standard practice in skinned fiber experiments as in some protocols actomyosin ATPase rate and cTnC Ca^{2+} -binding is measured simultaneously with force. Azide prevents mitochondrial ATP hydrolysis which would mask the sarcomere ATPase rate and inhibits mitochondrial Ca^{2+} -binding and uptake. Together with solubilization of mitochondria with Triton X-100, sodium azide assures that the measurements reflect the activity of sarcomeres. The solutions employed in the skinned fiber experiments contain high physiological levels of MgATP that is buffered with phosphocreatine (creatine phosphate). Creatine phosphate is important for proper buffering of the sarcomeric ATP and ADP changes that would otherwise affect contractile activity. Addition of creatine phosphokinase is required to catalyze the phosphate transfer from creatine phosphate to ADP and provides a supplement to the endogenous creatine kinase (Roche et al., 2015).

Protease inhibitors (pepstatin A 2.5 $\mu\text{g/ml}$; leupeptin, 1 $\mu\text{g/ml}$; phenylmethylsulphonyl fluoride [PMSF], 50 $\mu\text{mol/l}$) were included in solutions. Following isolation, fiber bundles were immersed in 1% Triton X-100 in HR for 30 min at room temperature and then returned to HR without Triton. After the detergent skinning, fibers were transferred to HR solution and kept briefly on ice. Fibers were mounted between the arm of a micro-manipulator and a force transducer and immersed in HR solution containing 0.06% dimethylsulfoxide (DMSO, the drug vehicle). Sarcomere length was adjusted with a micro-manipulator to 2.2 μm using the diffraction pattern generated from a helium-neon laser and kept constant during the protocol. In a second set of experiments, we carried out the same procedures with fiber bundles from 7- and 14-day old NTG mice and TG mice expressing cTnT-R92Q. In this case the 7-day old mice were decapitated, and the 14-day old mice were anesthetized with isoflurane before extracting the

hearts. Fiber bundles were then skinned in 1% Triton X-100, for either 10 min (7-day) or 20 min (14-day).

Determination of Ca²⁺-Dependence of Tension Developed in Skinned Fibers

Tension developed in the skinned fibers was measured over a range of free Ca²⁺ concentrations expressed as pCa (−log [Ca²⁺]) values. The pCa solutions were prepared by mixing various ratios of HR with 9.98 mM CaCl₂ (pCa 4.5). We added 0.1 μM creatine phosphokinase in all solutions; addition of creatine phosphokinase supplements the endogenous kinase to ensure transfer of phosphoryl group transfer from creatine phosphate to ADP (Roche et al., 2015). The solutions also contained 0.06% DMSO, 0.3 μM OM or 0.3 μM Mava in 0.06% DMSO. Ratios of HR and 9.98 mM CaCl₂ used to generate a range of pCa 7.0 to pCa 5.5 were calculated using WEBMAXC Standard. All experiments were performed at 22°C (Lamb and Stephenson, 2018), as chemically skinned fibers are more stable in sub physiological temperature, which further allows reproducibility of the measurements. We initially induced maximum tension at pCa 4.5, relaxed the fibers in HR with DMSO, and determined the diameter and width of the fiber bundle at 3 points for calculation of cross-sectional area. After a 5 min pre-incubation period in HR-DMSO, we recorded developed tension over the range of pCa values with a chart recorder. Following a 5 min pre-incubation with HR containing either 0.3 μM OM or 0.3 μM Mava, the measurements were repeated with the same fiber bundle in the range of pCa solutions containing either Mava (0.3 μM) or OM (0.3 μM). These drug concentrations are based on our previous studies as well as reports from other labs investigating force development in skinned fibers from human and animal hearts (Awinda et al., 2021; Green et al., 2016; Malik et al., 2011; Mamidi et al., 2018; Planelles-Herrero et al., 2017; Sparrow et al., 2020; Utter et al., 2015). Skinned fibers were checked for maintenance of maximum tension. The pCa-tension data were fit to the following equation:

$$F = Y_0 + A \times ([Ca^{2+}]^{nH} / (-\log_{10} [pCa_{50}]^{nH} + [Ca^{2+}]^{nH}))$$

pCa_{50} is the negative logarithm of $[Ca^{2+}]$ at half-maximum tension generation, nH is the Hill coefficient, Y_0 is the baseline, and A is the amplitude.

Gel Electrophoresis and Western Blot Analysis

To separate troponin I isoforms, 12% sodium dodecyl phosphate polyacrylamide gel electrophoresis (SDS-PAGE) was performed and transferred to Immun-Blot PVDF membrane (BioRad) as previously described (Warren et al., 2010) with BioRad's Criterion gel box and blotter. To separate troponin T isoforms and the R92Q mutant 8% total acrylamide, 1.1% Bis-acrylamide cross-linked SDS-PAGE gels (Anderson et al., 1991) were run in a large format gel box (SE600 Hoefer). The large gel was cut down to fit into a BioRad Criterion blotter to transfer the protein onto Immun-Blot PVDF (BioRad) to perform Western blot analysis. The whole homogenate samples for this study were prepared as described (Batra et al., 2021). The troponin separations were loaded at 10 μ g/lane and the myosin heavy chain (MHC) separations were loaded at 2.7 μ g/lane. The protein concentrations for all samples were determined with Thermo Scientific's 660nm protein assay with the ionic detergent compatibility reagent added. The myosin heavy chain isoform separation was performed as previously described (Warren and Greaser, 2003) and the bands were detected with Coomassie G-250. Image acquisition for both Western blots and Coomassie stained gels was done with BioRad's Chemidoc MP imager. Gel bands and Western blot densitometric analysis was done with Image lab v 6.01 (BioRad) and ratio analysis was done with Microsoft Excel 365.

Data and Statistical Analysis

The experiments performed in this study were exploratory in nature and did not employ a predefined plan, thus P values are descriptive. Tension was calculated as force per cross-sectional area. We fit the relation between developed isometric tension pCa by a nonlinear least squares regression analysis to the Hill's equation as described above. A two-way analysis of

variance with a Tukey post hoc adjusted P value for multiple comparisons method was used (GraphPad Prism v9.1.2) to compare maximum tension, pCa_{50} , Hill slope, and protein isoform distributions as indicated in figure and table legends. Data exclusion criteria were set in advance utilizing the ROUT outlier test in GraphPad Prism v9.1.2 with the Q-value set at 0.05. Data sets for two-way ANOVA's were normally distributed as assessed in GraphPad Prism v9.1.2 by Shapiro-Wilk or D'Agostino-Pearson omnibus (K2), in addition, homogeneity of variance was tested by Brown-Forsythe and Bartlett's tests. Where binary comparisons were appropriate an unpaired two-tailed t-test was performed where all data were normally distributed, but if the normality and equal variances assumptions were violated, we performed a Mann-Whitney test or an unpaired two-tailed t-test with Welch's correction respectively. For the comparison of changes in tension expressed as a percent of control tension, a pair-wise comparison between non-treated and treated fibers was performed, followed by an unpaired two-tailed t-test between only the treated fibers. Data are presented as means $\pm$ standard deviation with a level of significance set at $P < 0.05$.

Results

Protein Isoform Profiles of Skinned Fiber Bundles

To investigate the effect of the presence of the fetal/neonatal isoform, ssTnI on pCa-tension relations of skinned fibers treated either with vehicle or with a sarcomere activator (OM) and a sarcomere inhibitor (Mava), in the first set of experiments, we employed skinned fibers from hearts of adult NTG mice and adult TG mice harboring a transgene expressing ssTnI in place of cTnI in the cardiac compartment. Previous studies have documented that the expression and stoichiometry of the sarcomeric proteins including TnI are unaffected in the TG-ssTnI sarcomeres compared to controls (Fentzke et al., 1999). We also employed fibers from hearts of NTG 7-day and 14-day old NTG or TG-cTnT-R92Q mice naturally expressing variations in ssTnI during development with and without expression of an HCM-linked mutant cTnT. Figure 2 shows Western blot analysis probing for cTnI, ssTnI, cTnT, and cTnT-R92Q in whole heart homogenates. As illustrated in Figure 2A and B, the adult TG-ssTnI hearts expressed 100% ssTnI, whereas NTG littermates expressed 100% cTnI. In 7-day old NTG hearts percent abundance of ssTnI was 55.3% and the 7-day old TG-cTnT-R92Q hearts were 63.4% (Fig. 2 A-C and Supplemental Fig. S1). In 14-day old NTG and TG-cTnT-R92Q mice there was no detectable ssTnI isoform. The abundance of cTnT-R92Q in cTnT-R92Q hearts at 14 days was 74.7% vs. 47.1% in the 7-day old cTnT-R92Q hearts (Fig. 2 D-F and Supplemental Fig. S1). The myosin heavy chain (MHC) isoform population, detected by SDS-PAGE Coomassie stained gels, was unaffected by the presence of ssTnI or cTnT-R92Q mutant (Fig. 2, G-I). As expected, we observed statistically significant changes in the population of MHC isoforms (α and β) with aging from 7-14 days (Fig. 2 G and I).

Studies with omecamtiv mecarbil

Figure 3A shows pCa-tension relations of skinned fiber bundles from hearts of 4-month-old adult control NTG and TG-ssTnI mice with and without treatment with OM. In these experiments, we treated the skinned fibers with 0.3 μ M OM based on dose response relations determined in the present experiments and in our previous publications (Broughton et al., 2016; Utter et al., 2015). The parameters describing the pCa-tension relations are maximum tension (Fig. 3B; Table 1), Ca^{2+} -sensitivity as quantified by the pCa_{50} (-log of the half-maximally activating molar Ca^{2+} concentration) (Fig. 3C; Table 1), and the steepness of the curves, reflecting cooperative activation (Arteaga et al., 2000; Solis and Solaro, 2021) and quantified by nH, the Hill coefficient (Fig. 3D; Table 1). There was a difference in maximum tension developed by the skinned fibers from NTG and TG-ssTnI hearts – NTG developed 25.85% higher maximal value ($P=0.0319$), but no effect of OM on these tensions (Fig. 3B, Table 1). Without OM, as expected (Arteaga et al., 2000; Fentzke et al., 1999) myofilaments controlled by ssTnI were more sensitive (by 3.74%) to Ca^{2+} compared to myofilaments controlled by cTnI ($P=0.0002$) (Fig. 3C, Table 1). OM increased the pCa_{50} in both NTG by 2.81% ($P=0.035$) and in TG-ssTnI by 2.20% ($P=0.0164$) fibers. Although the change (Δ) in pCa_{50} induced by OM was 0.16 pCa units in the NTG and 0.13 in the TG-ssTnI myofilaments, (Fig. 3C, Table 1), the Ca^{2+} -sensitivity of the OM treated TG-ssTnI fibers was 3.12% greater than the Ca^{2+} -sensitivity of the OM treated NTG fibers ($P=0.0164$ vs. $P=0.035$). Without OM, compared to the NTG controls, TG-ssTnI fibers demonstrated 44.75% smaller slope of the Ca^{2+} -tension relation ($P<0.0001$) (Fig. 3D, Table 1). OM induced a 2.72-fold greater depression (Δ nH = 3.16) in NTG compared to TG-ssTnI fibers (Δ nH = 1.16) such that the nH in the presence of OM was 21.54% lower in NTG when compared to TG-ssTnI fibers ($P=0.0027$) (Fig. 3D, Table 1). To determine more clearly the effect of OM on the skinned fibers, we plotted the percent of control tension over a range of pCa values likely to be achieved physiologically (Fig. 3E, Supplemental Table S1). This analysis revealed that the percent increases in tension at these pCa values were higher in the NTG vs

TG-ssTnI fibers treated with OM by 427.40% at pCa 6.00 ($P=0.0082$), 137.40% at pCa 5.85 ($P=0.0266$) and by 48.3% at pCa 5.75 ($P=0.0079$).

To test the effect of OM on fiber bundles from neonatal mouse hearts demonstrating natural switching from ssTnI to cTnI as illustrated in Figure 2, we performed experiments on skinned fibers from 7-day and 14-day old mouse hearts. Figure 4A compares the pCa-tension relations of these fibers with and without additions of 0.3 μM OM. Without OM, the maximum tension developed by the 7-day fibers was 25.83% lower than the maximum tension developed by the 14-day fibers ($P=0.0035$); treatment with OM had no effect on these tensions (Fig. 4B, Table 2). Without OM the Ca^{2+} -sensitivity of 7-day fibers was 1.43% greater than the Ca^{2+} -sensitivity of the 14-day fibers ($P=0.0202$) (Fig. 4C, Table 2). However, whereas there was a clear effect of 0.3 μM OM on pCa_{50} of fibers from 7-day old hearts ($P<0.0001$) by 3.21%, there was a non-significant effect (increase by 1.10%) of OM on pCa_{50} of fibers from 14-day old hearts (Fig. 4C, Table 2). Without OM, the nH values were 29.77% lower in the 7-day fibers ($P=0.0037$) compared to the 14-day fibers (Fig. 4D, Table 2). Treatment with OM did not induce a change in nH values in the 7-day fibers, but OM did induce a 39.30% decrease in the nH values in 14-day skinned fibers ($P=0.0003$) (Fig. 4D, Table 2). Analysis of percent changes in tension induced by OM over a range of physiological pCa values demonstrated a trend toward a greater relative effect of OM at pCa 6.0 that did not reach statistical significance between treated groups. There were similar percent changes in tension at other pCa values (Fig. 4E; Supplemental Table S1). In summary, in 7-day immature skinned fibers expressing different myofilament isoforms than the 14-day fibers, there were different effects of OM on Ca^{2+} -sensitivity and cooperative activation. Yet OM induced similar relative increases in tension over the physiological range of pCa values.

Studies with mavacamten

In the next series of experiments, illustrated in Figure 5, summarized in Table 3 and Supplemental Table S1, we compared the effects of the sarcomere inhibitor, Mava, on pCa-tension relations in skinned fibers isolated from adult hearts of NTG controls and TG-ssTnI mice. Figure 5A illustrates the results of experiments testing the effect of Mava on pCa-tension relations of the NTG and TG-ssTnI myofilaments. The results demonstrate the sarcomere inhibiting activity of Mava by the fall in maximum tension in skinned fibers, which was nearly the same in myofilaments regulated by cTnI (47% inhibition, $P=0.0001$) than by ssTnI (52% inhibition, ($P<0.0001$)) (Fig. 5B and E; Table 3). Mava had a somewhat bigger effect in decreasing the Ca^{2+} -sensitivity of the TG-ssTnI fibers (decrease by 2.55%) with a $\Delta\text{pCa}_{50} = 0.15$ units, whereas in NTG fibers (decrease by 2.17%) the $\Delta\text{pCa}_{50} = 0.12$ units, which did not reach significance (Fig. 5C; Table 3). Mava did not induce changes in the nH values of either the TG-ssTnI or NTG fibers vs the controls (Fig. 5D; Table 3). Data shown in Figure 5E and summarized in Supplemental Table S1, show that the inhibition of tension shown as percent change was similar across the sub-maximum pCa values in the physiological range.

To further probe and compare the effects of Mava on sarcomeres controlled by cTnI and ssTnI, we tested its effects on skinned fibers isolated from perinatal hearts of 7-day old and 14-day old NTG mice and TG mice expressing cTnT-R92Q, a mutant linked to HCM (Figs. 6 and 7; Table 4-5). Data in Figure 6, summarized in Table 4, compare pCa-tension relations in skinned fibers from NTG controls and TG-cTnT-R92Q 7-day hearts with and without treatment with Mava. Without Mava, there were no differences between maximum tension, pCa_{50} , or nH values in the 7-day NTG and 7-day TG-cTnT-R92Q fibers (Fig. 6A-5D, Table 4). Treatment with Mava reduced the maximum tension in both groups (by 50.65% for NTG, $P=0.0186$; and by 47.62% for TG-cTnT-R92Q, $P=0.0004$) (Fig. 6A and 6B) with no effect on the pCa_{50} (Fig. 6C, Table 4), or nH values (Fig. 6D, Table 4). The depression in tension induced by Mava was ~50% over a range of sub-maximum pCa values (Fig. 6E, Supplemental Table S1). Data in Figure 7,

summarized in Table 5 and Supplemental Table S1, compare pCa-tension relations in skinned fibers from NTG controls and TG-cTnT-R92Q 14-day hearts with and without treatment with Mava. Without Mava, there was no difference between maximum tension developed by NTG and TG-cTnT-R92Q 14-day fibers (Fig. 7A-B and Table 5). However, in contrast to the 7-day data, at 14-days without Mava, pCa₅₀ was 2.88% higher in the TG-cTnT-R92Q fibers than in the NTG fibers (P=0.0022) (Fig. 7C and Table 5). At 14-days of age, TG-cTnT-R92Q fibers also had ~~significantly~~ 46.34% lower nH values compared to the NTG fibers (P<0.0001) (Fig. 7D and Table 5). Treatment with Mava reduced the maximum tension similarly in the 14-day NTG (reduction by 49.68%, P=0.0013) and in TG-cTnT-R92Q (reduction by 43.96%, P=0.0025) (Fig. 7A-B and Table 5). Whereas there was no effect of Mava on the pCa₅₀ of the 14-day NTG fibers (Fig. 7C, Table 5), Mava induced a 3.16% decrease in the pCa₅₀ of the TG-cTnT-R92Q fibers (P=0.0034) (Fig. 7C, Table 5). Values of nH were not changed by Mava in either the 14-day NTG or TG-cTnT-R92Q fibers (Fig. 7D, Table 5). The depression in tension at sub-maximum pCa values induced by Mava ranged from 11.09% in the NTG 14-day fibers to 38.15% in the 14-day TG-TnT-92Q fibers (at pCa 5.85 P=0.0251; at pCa 5.75 P=0.0210) (Fig. 7E, Supplemental Table S1). In summary, these data indicate that at 7-days, the effect of Mava to act as a sarcomere inhibitor is *via* a depression in tension generation with no effect on pCa₅₀ or nH values and independent of the presence of ssTnI and cTnT-R92Q in the myofilaments. However, at 14 days, when ssTnI has been replaced by cTnI, and when a larger proportion of cTnT has been replaced by cTnT-R92Q than at 7 days, Mava induced a greater relative depression in NTG vs. TG fiber tension at sub-maximal pCa values in conjunction with an effect to reduce the pCa₅₀ only in the cTnT-R92Q fiber bundles.

Discussion

Mechanisms of OM Activation and Mava Inhibition Involve Integrated Effects of Sarcomere Proteins Beyond Myosin

Our studies of the effects of OM and Mava on Ca^{2+} -activation of skinned ventricular fiber bundles expressing either cTnI or ssTnI provide novel insights into their mechanisms of action. These mechanisms are relevant to the development of new sarcomere inhibitors and activators likely to be screened to improve therapeutic index and pharmacokinetic properties. Abundant evidence demonstrates that a key step in screening sarcomere activators and inhibitors is an *in vitro* determination of sarcomere response to Ca^{2+} . The effect of Mava and OM to modify Ca^{2+} -force relations of skinned fiber preparations encouraged development to the next stage eventually leading to studies in myocytes, hearts, animal models, and human safety trials (Green et al., 2016; Morgan et al., 2010). Our data are also relevant to the use of immature cardiac myocytes, often expressing ssTnI, derived from human inducible pluripotent stem cells and proposed for use in drug development and diagnosis (Wheelwright et al., 2020) (Andrysiak et al., 2021).

To illuminate mechanisms affected by OM and Mava, Figure 8 depicts thin and thick filament control of myofilament force generation. Included in Figure 8 are recent revelations on the dispositions of the cross-bridges in two headed myosin in a super relaxed state (SRX) with the heads folded back and a disordered relaxed state (DRX) poised for interaction with the thin filaments (Anderson et al., 2018; Toepfer et al., 2020). In addition, an important revelation is the evidence that both TnI and TnT are in an extended state interacting with all the actins in a regulatory unit, and thus likely to be involved not only in the Ca^{2+} switch but also in the near neighbor interactions among the regulatory units (Solis and Solaro, 2021; Tobacman and Cammarato, 2021; Yamada et al., 2020). Figure 8 indicates these cooperative interactions among the filaments and substantial isoform differences. In the case of ssTnI compared to

cTnI, these differences occur in the critical inhibitory peptide (Ip), switch peptide (Sw) and mobile C-terminal domain. cTnT-R92Q is in a critical helical region (cTnT-87-150) that provides an anchor to the thin filament essential in the transduction of the Ca^{2+} -binding signal and the interaction between contiguous peptides in the Tm strand (Tobacman and Cammarato, 2021).

The mechanisms currently proposed for the actions of OM, stress its effects on myosin kinetics, the dwell time of the force generating cross-bridges on the thin filament, or the population of cross-bridges in SRX and DRX states. There has been some, but little consideration of the potential that these effects are influenced by the thin filaments, their isoforms, or proteins associated with the thick filaments such as cMyBP-C. Similarly, with Mava the proposed mechanism focuses on shifts in the population of cross-bridges to the SRX state (Anderson et al., 2018).

Molecular Mechanisms of OM in Developing Cardiac Sarcomeres

Effects of OM in our studies included increases in sub-maximum tension with modifications of cooperative activation and Ca^{2+} -sensitivity. The effect of OM to increase sub-maximum tension developed by cTnI-myofilaments compared to ssTnI-myofilaments stresses how a change in cooperativity has impactful effects on tension developed in addition to modifications in Ca^{2+} -sensitivity. In agreement with our studies with cardiac fibers, studies on slow skeletal fibers reported a substantial effect of OM to increase Ca^{2+} -sensitivity, with a large effect at submaximal Ca^{2+} concentrations and a decrease in nH (Governali et al., 2020; Lindqvist et al., 2019; Nagy et al., 2015). As illustrated in Figure 8, OM is likely to modify cooperative activation by a mechanism involving an interaction of force generating cross-bridges with thin filaments inducing movements in Tm or altered actin-actin interactions modifying the spread of activation from an active regulatory unit to a near neighbor regulatory unit. The influence of effects of OM on the interaction between myosin S-2 and cMyBP-C may also be a factor (Mamidi et al., 2015). Although isoform shifts were not studied, there are reports supporting our conclusion that thin

filament activation is at play in the effects of OM (Kampourakis et al., 2018; Woody et al., 2018). Woody et al. (2018). reported that the increase in force induced by OM is associated with a suppression of the working stroke of cardiac myosin together with thin filament activation. Kampourakis et al. (2018) reported that the modification of cross-bridge state induced by OM in adult skinned fibers also increased Ca^{2+} -sensitivity. Mamidi et al. (2015) reported the effects of OM to alter function in skinned fibers lacking MyBP-C in a way suggesting that it may be useful in hypercontractile states in HCM models with deletion mutations in MyBP-C. In this case the actions of OM are opposite of its proposed effects to enhance contractility.

Molecular Mechanisms of Mava in Inhibition of Developing Cardiac Sarcomeres

Data presented here are the first to report the effects of Mava on Ca^{2+} -activation of skinned ventricular fibers expressing either cTnI or ssTnI with and without expression of an HCM-linked mutant, cTnT-R92Q. Inhibition of maximum and sub-maximum tension values was the same in adult myofilaments expressing either cTnI or ssTnI in place of cTnI. However, the influence of thin filament state on the effect of Mava was indicated by the demonstration that in the presence of Mava, nH values were different in NTG fibers than in TG-ssTnI fibers. The use of probes as reporters of Ca^{2+} localized at the thin filament indicate an effect of Mava on thin filament activation that may be different in cTnI-sarcomeres vs. ssTnI-sarcomeres. These studies report little change in the peak values of Ca^{2+} -troponin binding induced by Mava, but a considerable effect on the rate of binding and release from troponin (Sparrow et al., 2019). This interpretation is tempered by the use of unloaded myocytes. Sparrow et al. (2020) reported no effect of Mava on ATPase rate in control unloaded reconstituted myofilament preparations and a very small effect in preparations with thin filament HCM linked mutations. A weakness of these studies is the use of unloaded reconstituted preparations lacking critical proteins in the myofilament lattice.

Therapy Development and Effects of OM and Mava in Immature Myofilaments

Importantly, our study extends the understanding of how OM and Mava affect sarcomere tension which, supports the need for re-thinking the mechanisms of their actions and the mechanisms of action of new sarcomere activators and inhibitors likely to be developed. An encouraging aspect of the application of data presented here in future drug development, is the success of safety trials with OM and Mava. As reported by (Teerlink et al., 2020; Teerlink et al., 2021), there were minimal side effects in the OM clinical trials. Similarly, (Olivotto et al., 2020) reported minimal side effects of Mava in the EXPLORER-HCM clinical trial. A recent study (Barrick et al., 2021), relevant to studies reported here, emphasizes the significance of understanding detailed mechanisms of action of sarcomere activators and inhibitors in precision medicine applied in pediatric cardiology. They investigated one of several mutants (cTnT-R134G) linked to pediatric dilated cardiomyopathy (DCM) progressing to pediatric heart failure (Hershberger et al., 2009). In myofilaments controlled by cTnT-R134G, Ca^{2+} -cTnC was unable to switch on the myofilaments and cross-bridge interactions could not activate the thin filament. As pointed out by Barrick et al. (2021) in this cardiac disorder the use of OM to increase contractility, which we show can activate the thin filament in immature myofilaments, would be preferred over activators (for example levosimendan) promoting transduction of the cTnC Ca^{2+} -binding signal (Klein et al., 2018).

In summary, despite different mechanisms of action to activate and inhibit sarcomere tension, effects of OM and Mava are similar in immature and mature myofilaments. However, the mechanisms in mature and immature sarcomeres involve not only induction of DRX and SRX states but also modifications in the mechanism related to cooperative activation of the myofilaments. The results are also related to screening for sarcomere activators and inhibitors using cardiac myocytes derived from hiPSCs, which are generally immature and express ssTnl. A relevant finding reported in our previous studies is the demonstration that OM induced

activation of sarcomeres from hearts of a DCM model (Tm-E54K) (Utter et al., 2015), in hiPSC-CMs expressing ssTnI and DCM mutant cTnT R173W (Broughton et al., 2016). More recently, (Rhoden et al., 2022) also reported effects of OM on engineered human cardiac preparations likely to contain ssTnI.

Acknowledgments None.

Authorship Contributions

Participated in research design: Halas, Langa, Warren, Solaro.

Conducted experiments: Halas, Warren.

Performed data analysis: Halas, Langa, Warren, Solaro

Wrote or contributed to the writing of the manuscript: Halas, Langa, Warren, Goldspink, Wolska, Solaro.

References

- Alves ML, Warren CM, Simon JN, Gaffin RD, Montminy EM, Wieczorek DF, Solaro RJ and Wolska BM (2017) Early sensitization of myofilaments to Ca²⁺ prevents genetically linked dilated cardiomyopathy in mice. *Cardiovasc Res* **113**(8): 915-925.
- Anderson PA, Malouf NN, Oakeley AE, Pagani ED and Allen PD (1991) Troponin T isoform expression in humans. A comparison among normal and failing adult heart, fetal heart, and adult and fetal skeletal muscle. *Circ Res* **69**(5): 1226-1233.
- Anderson RL, Trivedi DV, Sarkar SS, Henze M, Ma W, Gong H, Rogers CS, Gorham JM, Wong FL, Morck MM, Seidman JG, Ruppel KM, Irving TC, Cooke R, Green EM and Spudich JA (2018) Deciphering the super relaxed state of human β -cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers. *Proc Natl Acad Sci U S A* **115**(35): E8143-E8152.
- Andrysiak K, Stępniewski J and Dulak J (2021) Human-induced pluripotent stem cell-derived cardiomyocytes, 3D cardiac structures, and heart-on-a-chip as tools for drug research. *Pflugers Arch* **473**(7): 1061-1085.
- Arteaga GM, Palmiter KA, Leiden JM and Solaro RJ (2000) Attenuation of length dependence of calcium activation in myofilaments of transgenic mouse hearts expressing slow skeletal troponin I. *J Physiol* **526 Pt 3**: 541-549.
- Awinda PO, Watanabe M, Bishaw Y, Huckabee AM, Agonias KB, Kazmierczak K, Szczesna-Cordary D and Tanner BCW (2021) Mavacamten decreases maximal force and Ca(2+) sensitivity in the N47K-myosin regulatory light chain mouse model of hypertrophic cardiomyopathy. *Am J Physiol Heart Circ Physiol* **320**(2): H881-H890.
- Barrick SK, Greenberg L and Greenberg MJ (2021) A Troponin T Variant Linked with Pediatric Dilated Cardiomyopathy Reduces the Coupling of Thin Filament Activation to Myosin and Calcium Binding. *Mol Biol Cell*: mbcE21020082.

- Batra A, Warren CM, Ke Y, McCann M, Halas M, Capote AE, Liew CW, Solaro RJ and Rosas PC (2021) Deletion of P21-activated kinase-1 induces age-dependent increased visceral adiposity and cardiac dysfunction in female mice. *Mol Cell Biochem* **476**(3): 1337-1349.
- Broughton KM, Li J, Sarmah E, Warren CM, Lin YH, Henze MP, Sanchez-Freire V, Solaro RJ and Russell B (2016) A myosin activator improves actin assembly and sarcomere function of human-induced pluripotent stem cell-derived cardiomyocytes with a troponin T point mutation. *Am J Physiol Heart Circ Physiol* **311**(1): H107-117.
- Chowdhury SAK, Warren CM, Simon JN, Ryba DM, Batra A, Varga P, Kranias EG, Tardiff JC, Solaro RJ and Wolska BM (2020) Modifications of Sarcoplasmic Reticulum Function Prevent Progression of Sarcomere-Linked Hypertrophic Cardiomyopathy Despite a Persistent Increase in Myofilament Calcium Response. *Front Physiol* **11**: 107.
- Fentzke RC, Buck SH, Patel JR, Lin H, Wolska BM, Stojanovic MO, Martin AF, Solaro RJ, Moss RL and Leiden JM (1999) Impaired cardiomyocyte relaxation and diastolic function in transgenic mice expressing slow skeletal troponin I in the heart. *J Physiol* **517 (Pt 1)**: 143-157.
- Governali S, Caremani M, Gallart C, Pertici I, Stienen G, Piazzesi G, Ottenheijm C, Lombardi V and Linari M (2020) Orthophosphate increases the efficiency of slow muscle-myosin isoform in the presence of omecamtiv mecarbil. *Nat Commun* **11**(1): 3405.
- Green EM, Wakimoto H, Anderson RL, Evanchik MJ, Gorham JM, Harrison BC, Henze M, Kawas R, Oslob JD, Rodriguez HM, Song Y, Wan W, Leinwand LA, Spudich JA, McDowell RS, Seidman JG and Seidman CE (2016) A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. *Science* **351**(6273): 617-621.
- Hershberger RE, Pinto JR, Parks SB, Kushner JD, Li D, Ludwigsen S, Cowan J, Morales A, Parvatiyar MS and Potter JD (2009) Clinical and functional characterization of TNNT2

- mutations identified in patients with dilated cardiomyopathy. *Circ Cardiovasc Genet* **2**(4): 306-313.
- Ho CY, Olivotto I, Jacoby D, Lester SJ, Roe M, Wang A, Waldman CB, Zhang D, Sehnert AJ and Heitner SB (2020) Study Design and Rationale of EXPLORER-HCM: Evaluation of Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy. *Circulation Heart failure* **13**(6): e006853.
- Hunkeler NM, Kullman J and Murphy AM (1991) Troponin I isoform expression in human heart. *Circ Res* **69**(5): 1409-1414.
- Kampourakis T, Zhang X, Sun YB and Irving M (2018) Omecamtiv mercabil and blebbistatin modulate cardiac contractility by perturbing the regulatory state of the myosin filament. *J Physiol* **596**(1): 31-46.
- Klein BA, Reiz B, Robertson IM, Irving M, Li L, Sun YB and Sykes BD (2018) Reversible Covalent Reaction of Levosimendan with Cardiac Troponin C in Vitro and in Situ. *Biochemistry* **57**(15): 2256-2265.
- Lamb GD and Stephenson DG (2018) Measurement of force and calcium release using mechanically skinned fibers from mammalian skeletal muscle. *Journal of applied physiology* **125**(4): 1105-1127.
- Layland J, Solaro RJ and Shah AM (2005) Regulation of cardiac contractile function by troponin I phosphorylation. *Cardiovasc Res* **66**(1): 12-21.
- Lindqvist J, Lee EJ, Karimi E, Kolb J and Granzier H (2019) Omecamtiv mecarbil lowers the contractile deficit in a mouse model of nebulin-based nemaline myopathy. *PLoS One* **14**(11): e0224467.
- Malik FI, Hartman JJ, Elias KA, Morgan BP, Rodriguez H, Brejc K, Anderson RL, Sueoka SH, Lee KH, Finer JT, Sakowicz R, Baliga R, Cox DR, Garard M, Godinez G, Kawas R, Kraynack E, Lenzi D, Lu PP, Muci A, Niu C, Qian X, Pierce DW, Pokrovskii M, Suehiro I, Sylvester S, Tochimoto T, Valdez C, Wang W, Katori T, Kass DA, Shen YT, Vatner SF

- and Morgans DJ (2011) Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. *Science* **331**(6023): 1439-1443.
- Mamidi R, Gresham KS, Li A, dos Remedios CG and Stelzer JE (2015) Molecular effects of the myosin activator omecamtiv mecarbil on contractile properties of skinned myocardium lacking cardiac myosin binding protein-C. *J Mol Cell Cardiol* **85**: 262-272.
- Mamidi R, Li J, Doh CY, Verma S and Stelzer JE (2018) Impact of the Myosin Modulator Mavacamten on Force Generation and Cross-Bridge Behavior in a Murine Model of Hypercontractility. *J Am Heart Assoc* **7**(17): e009627.
- Metzger JM, Michele DE, Rust EM, Borton AR and Westfall MV (2003) Sarcomere thin filament regulatory isoforms. Evidence of a dominant effect of slow skeletal troponin I on cardiac contraction. *J Biol Chem* **278**(15): 13118-13123.
- Michele DE, Gomez CA, Hong KE, Westfall MV and Metzger JM (2002) Cardiac dysfunction in hypertrophic cardiomyopathy mutant tropomyosin mice is transgene-dependent, hypertrophy-independent, and improved by beta-blockade. *Circ Res* **91**(3): 255-262.
- Morgan BP, Muci A, Lu PP, Qian X, Tochimoto T, Smith WW, Garard M, Kraynack E, Collibee S, Suehiro I, Tomasi A, Valdez SC, Wang W, Jiang H, Hartman J, Rodriguez HM, Kawas R, Sylvester S, Elias KA, Godinez G, Lee K, Anderson R, Sueoka S, Xu D, Wang Z, Djordjevic N, Malik FI and Morgans DJ, Jr. (2010) Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac Myosin. *ACS Med Chem Lett* **1**(9): 472-477.
- Murphy AM, Jones L, 2nd, Sims HF and Strauss AW (1991) Molecular cloning of rat cardiac troponin I and analysis of troponin I isoform expression in developing rat heart. *Biochemistry* **30**(3): 707-712.
- Nagy L, Kovács Á, Bódi B, Pásztor ET, Fülöp G, Tóth A, Édes I and Papp Z (2015) The novel cardiac myosin activator omecamtiv mecarbil increases the calcium sensitivity of force

- production in isolated cardiomyocytes and skeletal muscle fibres of the rat. *British journal of pharmacology* **172**(18): 4506-4518.
- Olivotto I, Oreziak A, Barriales-Villa R, Abraham TP, Masri A, Garcia-Pavia P, Saberi S, Lakdawala NK, Wheeler MT, Owens A, Kubanek M, Wojakowski W, Jensen MK, Gimeno-Blanes J, Afshar K, Myers J, Hegde SM, Solomon SD, Sehnert AJ, Zhang D, Li W, Bhattacharya M, Edelberg JM, Waldman CB, Lester SJ, Wang A, Ho CY, Jacoby D and investigators E-Hs (2020) Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* **396**(10253): 759-769.
- Planelles-Herrero VJ, Hartman JJ, Robert-Paganin J, Malik FI and Houdusse A (2017) Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil. *Nat Commun* **8**(1): 190.
- Prabhakar R, Boivin GP, Grupp IL, Hoit B, Arteaga G, Solaro RJ and Wieczorek DF (2001) A familial hypertrophic cardiomyopathy alpha-tropomyosin mutation causes severe cardiac hypertrophy and death in mice. *J Mol Cell Cardiol* **33**(10): 1815-1828.
- Rhoden A, Schulze T, Pietsch N, Christ T, Hansen A and Eschenhagen T (2022) Comprehensive analyses of the inotropic compound omecamtiv mecarbil in rat and human cardiac preparations. *Am J Physiol Heart Circ Physiol*.
- Roche SM, Gumucio JP, Brooks SV, Mendias CL and Claflin DR (2015) Measurement of Maximum Isometric Force Generated by Permeabilized Skeletal Muscle Fibers. *J Vis Exp*(100): e52695.
- Rowlands CT, Owen T, Lawal S, Cao S, Pandey SS, Yang HY, Song W, Wilkinson R, Alvarez-Laviada A, Gehmlich K, Marston SB and MacLeod KT (2017) Age- and strain-related aberrant Ca(2+) release is associated with sudden cardiac death in the ACTC E99K mouse model of hypertrophic cardiomyopathy. *Am J Physiol Heart Circ Physiol* **313**(6): H1213-H1226.

- Ryba DM, Warren CM, Karam CN, Davis RT, 3rd, Chowdhury SAK, Alvarez MG, McCann M, Liew CW, Wieczorek DF, Varga P, Solaro RJ and Wolska BM (2019) Sphingosine-1-Phosphate Receptor Modulator, FTY720, Improves Diastolic Dysfunction and Partially Reverses Atrial Remodeling in a Tm-E180G Mouse Model Linked to Hypertrophic Cardiomyopathy. *Circulation Heart failure* **12**(11): e005835.
- Sasse S, Brand NJ, Kyprianou P, Dhoot GK, Wade R, Arai M, Periasamy M, Yacoub MH and Barton PJ (1993) Troponin I gene expression during human cardiac development and in end-stage heart failure. *Circ Res* **72**(5): 932-938.
- Solaro RJ, Henze M and Kobayashi T (2013) Integration of troponin I phosphorylation with cardiac regulatory networks. *Circ Res* **112**(2): 355-366.
- Solis C and Solaro RJ (2021) Novel insights into sarcomere regulatory systems control of cardiac thin filament activation. *J Gen Physiol* **153**.
- Sparrow AJ, Sievert K, Patel S, Chang YF, Broyles CN, Brook FA, Watkins H, Geeves MA, Redwood CS, Robinson P and Daniels MJ (2019) Measurement of Myofilament-Localized Calcium Dynamics in Adult Cardiomyocytes and the Effect of Hypertrophic Cardiomyopathy Mutations. *Circ Res* **124**(8): 1228-1239.
- Sparrow AJ, Watkins H, Daniels MJ, Redwood C and Robinson P (2020) Mavacamten rescues increased myofilament calcium sensitivity and dysregulation of Ca(2+) flux caused by thin filament hypertrophic cardiomyopathy mutations. *Am J Physiol Heart Circ Physiol* **318**(3): H715-H722.
- Tardiff JC, Hewett TE, Palmer BM, Olsson C, Factor SM, Moore RL, Robbins J and Leinwand LA (1999) Cardiac troponin T mutations result in allele-specific phenotypes in a mouse model for hypertrophic cardiomyopathy. *The Journal of clinical investigation* **104**(4): 469-481.
- Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Adams KF, Anand I, Arias-Mendoza A, Biering-Sorensen T, Bohm M, Bonderman D, Cleland JGF, Corbalan

- R, Crespo-Leiro MG, Dahlstrom U, Echeverria Correa LE, Fang JC, Filippatos G, Fonseca C, Goncalvesova E, Goudev AR, Howlett JG, Lanfear DE, Lund M, Macdonald P, Mareev V, Momomura SI, O'Meara E, Parkhomenko A, Ponikowski P, Ramires FJA, Serpytis P, Sliwa K, Spinar J, Suter TM, Tomcsanyi J, Vandekerckhove H, Vinereanu D, Voors AA, Yilmaz MB, Zannad F, Sharpsten L, Legg JC, Abbasi SA, Varin C, Malik FI, Kurtz CE and Investigators G-H (2020) Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials. *Eur J Heart Fail* **22**(11): 2160-2171.
- Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Adams KF, Anand I, Arias-Mendoza A, Biering-Sorensen T, Bohm M, Bonderman D, Cleland JGF, Corbalan R, Crespo-Leiro MG, Dahlstrom U, Echeverria LE, Fang JC, Filippatos G, Fonseca C, Goncalvesova E, Goudev AR, Howlett JG, Lanfear DE, Li J, Lund M, Macdonald P, Mareev V, Momomura SI, O'Meara E, Parkhomenko A, Ponikowski P, Ramires FJA, Serpytis P, Sliwa K, Spinar J, Suter TM, Tomcsanyi J, Vandekerckhove H, Vinereanu D, Voors AA, Yilmaz MB, Zannad F, Sharpsten L, Legg JC, Varin C, Honarpour N, Abbasi SA, Malik FI, Kurtz CE and Investigators G-H (2021) Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. *N Engl J Med* **384**(2): 105-116.
- Tobacman LS and Cammarato A (2021) Cardiomyopathic troponin mutations predominantly occur at its interface with actin and tropomyosin. *J Gen Physiol* **153**(3).
- Toepfer CN, Garfinkel AC, Venturini G, Wakimoto H, Repetti G, Alamo L, Sharma A, Agarwal R, Ewoldt JF, Cloonan P, Letendre J, Lun M, Olivotto I, Colan S, Ashley E, Jacoby D, Michels M, Redwood CS, Watkins HC, Day SM, Staples JF, Padron R, Chopra A, Ho CY, Chen CS, Pereira AC, Seidman JG and Seidman CE (2020) Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic Cardiomyopathy. *Circulation* **141**(10): 828-842.

- Utter MS, Ryba DM, Li BH, Wolska BM and Solaro RJ (2015) Omecamtiv Mecarbil, a Cardiac Myosin Activator, Increases Ca²⁺ Sensitivity in Myofilaments With a Dilated Cardiomyopathy Mutant Tropomyosin E54K. *J Cardiovasc Pharmacol* **66**(4): 347-353.
- Ware SM, Wilkinson JD, Tariq M, Schubert JA, Sridhar A, Colan SD, Shi L, Canter CE, Hsu DT, Webber SA, Dodd DA, Everitt MD, Kantor PF, Addonizio LJ, Jefferies JL, Rossano JW, Pahl E, Rusconi P, Chung WK, Lee T, Towbin JA, Lal AK, Bhatnagar S, Aronow B, Dexheimer PJ, Martin LJ, Miller EM, Sleeper LA, Razoky H, Czachor J, Lipshultz SE and Pediatric Cardiomyopathy Registry Study G (2021) Genetic Causes of Cardiomyopathy in Children: First Results From the Pediatric Cardiomyopathy Genes Study. *J Am Heart Assoc* **10**(9): e017731.
- Warren CM, Geenen DL, Helseth DL, Jr., Xu H and Solaro RJ (2010) Sub-proteomic fractionation, iTRAQ, and OFFGEL-LC-MS/MS approaches to cardiac proteomics. *J Proteomics* **73**(8): 1551-1561.
- Warren CM and Greaser ML (2003) Method for cardiac myosin heavy chain separation by sodium dodecyl sulfate gel electrophoresis. *Anal Biochem* **320**(1): 149-151.
- Wheelwright M, Mikkila J, Bedada FB, Mandegar MA, Thompson BR and Metzger JM (2020) Advancing physiological maturation in human induced pluripotent stem cell-derived cardiac muscle by gene editing an inducible adult troponin isoform switch. *Stem Cells* **38**(10): 1254-1266.
- Woody MS, Greenberg MJ, Barua B, Winkelmann DA, Goldman YE and Ostap EM (2018) Positive cardiac inotrope omecamtiv mecarbil activates muscle despite suppressing the myosin working stroke. *Nat Commun* **9**(1): 3838.
- Yamada Y, Namba K and Fujii T (2020) Cardiac muscle thin filament structures reveal calcium regulatory mechanism. *Nat Commun* **11**(1): 153.

Zampieri M, Argiro A, Marchi A, Berteotti M, Targetti M, Fornaro A, Tomberli A, Stefano P, Marchionni N and Olivotto I (2021) Mavacamten, a Novel Therapeutic Strategy for Obstructive Hypertrophic Cardiomyopathy. *Curr Cardiol Rep* **23**(7): 79.

Footnotes

a) This work was supported by the National Institutes of Health at the National Heart Lung and Blood Institute [Grants RO1 HL128468, PO1 HL062426]; and the American Heart Association [grant #834691].

c) Correspondence for reprint requests:

R. John Solaro, PhD

Department of Physiology and Biophysics (M/C 901)

University of Illinois at Chicago, College of Medicine

835 South Wolcott Avenue RM. E-202

Chicago, IL 60612

solarorj@uic.edu

Financial Disclosure:

Dr. Solaro is a member of the Scientific Advisory Board of Cytokinetics, and a consultant to MyoKardia BMS, and Pfizer, Inc.

Figure Legends

Figure 1. Chemical structure depiction of (A) omecamtive mecarbil and (B) mavacamten.

Source: omecamtive mecarbil: National Center for Biotechnology Information (2022).

PubChem Compound Summary for CID 11689883, Omecamtiv mecarbil. Retrieved January 28, 2022 from <https://pubchem.ncbi.nlm.nih.gov/compound/Omecamtiv-mecarbil>; mavacamten:

National Center for Biotechnology Information (2022). PubChem Compound Summary for CID 117761397, Mavacamten. Retrieved January 28, 2022 from <https://pubchem.ncbi.nlm.nih.gov/compound/Mavacamten>.

Figure 2. Western blot and SDS-PAGE analysis demonstrating myofilament isoform abundance differences in adult and immature NTG and TG-cTnT-R92Q mouse hearts.

NTG, non-transgenic; TG-ssTnI, transgenic-slow skeletal troponin I; TG-cTnT-R92Q, transgenic cardiac troponin T with a single site mutation at position 92; day, age of animals in days; WT cTnT, wildtype cardiac troponin T. **(A)** Western blot probing for troponin I isoforms in adult samples, cardiac troponin I, (cTnI) and slow skeletal troponin I (ssTnI), with an antibody recognizing both isoforms simultaneously. **(B)** Histograms quantifying the percent of TG-ssTnI in the total TnI population of adult samples from panel A. **(C)** Histograms quantifying the percent of TG-ssTnI in the total TnI population of 7- and 14-days old samples from panel A. **(D)** Western blot probing for TnT isoforms with an antibody recognizing all isoforms simultaneously. **(E)** Histograms quantifying the percent of TG-cTnT-R92Q in the total TnT population of adult samples from panel D. **(F)** Histograms quantifying the percent of TG-cTnT-R92Q in the total TnT population of 7- and 14-days old samples from panel D. **(G)** Representative SDS-PAGE stained with Coomassie blue showing the myosin heavy chain (MHC) alpha (α) and beta (β) isoforms. **(H)** Histograms quantifying the percent of β -MHC/ total MHC in adult samples from panel G. Statistical significance was determined by an unpaired two-tailed T-test where no significance was found. **(I)** Histograms quantifying the percent of β -MHC/ total MHC in 7- and

14-days old samples from panel G. Data presented as means $\pm$ SD, $n=4$, $**P < 0.0042$, $****P < 0.0001$. Statistical significance was determined by 2-way ANOVA test followed with a Tukey's multiple comparison post-hoc test for panels C, F, and I. No statistical test was performed for panels B and E.

Figure 3. Effect of omecamtiv mecarbil on pCa-tension relations of skinned fiber bundles from hearts of adult control NTG mice and TG-ssTnl mice. (A) pCa-tension relations in NTG and TG adult mouse skinned fiber bundles $\pm$ OM treatment. **(B)** Scatter plot of maximum tension (mN/mm²). **(C)** Scatter plot of pCa₅₀ values. **(D)** Scatter plot of Hill Slopes (nH). **(E)** Activation represented as OM induced percent increase in control tension over a range of sub-maximum pCa values. Data presented as means $\pm$ SD, $n=5$, $*P < 0.05$, $**P < 0.01$, $***P < 0.001$, $****P < 0.0001$. Exact P-values are found in Table 1. Statistical significance was determined by 2-way ANOVA test followed with a Tukey's multiple comparison post-hoc test (A-D); and by unpaired two-tailed Student's t-test for (E).

Figure 4. Effect of omecamtiv mecarbil on pCa-tension relations of skinned fiber bundles from hearts of 7- and 14-day old NTG mice. (A) pCa-tension relations of NTG 7- and 14-day mouse skinned fiber bundles $\pm$ OM treatment. **(B)** Scatter plot of maximum tension (mN/mm²). **(C)** Scatter plot of pCa₅₀ values **(D)** Scatter plot of Hill Slopes (nH). **(E)** Activation represented as percent increase in control tension over a range of sub-maximum pCa values. Data presented as means $\pm$ SD, $n=6-7$, $*P < 0.05$, $**P < 0.01$, $***P < 0.001$, $****P < 0.0001$. Exact P-values are found in Table 2. Statistical significance was determined by 2-way ANOVA test followed with a Tukey's multiple comparison post-hoc test (A-D); and by unpaired two-tailed Student's t-test for (E).

Figure 5. Effect of mavacamten on pCa-tension relations of skinned fiber bundles from hearts of adult control NTG mice and TG-ssTnl mice. (A) pCa-tension relations in NTG and TG-ssTnl adult skinned fiber bundles $\pm$ Mava treatment. **(B)** Scatter plot of maximum tension

(mN/mm²). **(C)** Scatter plot of pCa₅₀ values. **(D)** Scatter plot of Hill Slopes (nH). **(E)** Inhibition represented as percent of control tension over a range of sub-maximum pCa values. Data represented as means $\pm$ SD, n=5-6, *, P < 0.05, ***, P<0.001, ****, P< 0.0001. Exact P-values are found in Table 3. Statistical significance was determined by 2-way ANOVA test followed with a Tukey's multiple comparison post-hoc test (A-D); and by unpaired two-tailed Student's t-test for (E).

Figure 6. Effect of mavacamten on pCa-tension relations of skinned fiber bundles from hearts of 7-day NTG and 7-day TG-cTnT-R92Q mice. **(A)** pCa-tension relations of NTG 7-day mouse skinned fiber bundles $\pm$ Mava treatment. **(B)** Scatter plot of maximum tension (mN/mm²). **(C)** Scatter plot of pCa₅₀ values. **(D)** Scatter plot of Hill Slopes (nH). **(E)** Inhibition represented as percent of control tension over a range of sub-maximum pCa values. Data presented as means $\pm$ SD, n=3-7, *P < 0.05, ***P<0.001. Exact P-values are found in Table 4. Statistical significance was determined by 2-way ANOVA test followed with a Tukey's multiple comparison post-hoc test (A, C-D); and by unpaired two-tailed Student's t-test for (E).

Figure 7. Effect of mavacamten on pCa-tension relations of skinned fiber bundles from hearts of 14-day old NTG mice and 14-day old TG-cTnT-R92Q mice. **(A)** pCa-tension relations of NTG 14-day skinned fiber bundles $\pm$ Mava treatment. **(B)** Scatter plot of max tension (mN/mm²). **(C)** Scatter plot of pCa₅₀ values. **(D)** Scatter plot of Hill Slope (nH). **(E)** Inhibition represented as percent of control tension over a range of sub-maximum pCa values. Data represented as mean $\pm$ SD, n = 4-5, *P < 0.05, **P< 0.01, ****P< 0.0001. Exact P-values are found in Table 5. Statistical significance was determined by 2-way ANOVA test followed with a Tukey's multiple comparison post-hoc test (A-D); and by unpaired two-tailed Student's t-test for (E). Data presented as means $\pm$ SD.

Figure 8. Mechanisms of Regulation of Cardiac Myofilament Activation Modified by Myosin Activators and Inhibitors. As shown by the right side of the figure, the reaction of

cross-bridges with thin filaments promotes ATP hydrolysis powering shortening and tension generation. At the level of the thin filaments, Ca-binding to cardiac troponin C (cTnC) triggers an interaction of a switch peptide (Sw) of the inhibitory protein (TnI) to switch on the thin filament and release the inhibition imposed by a TnI inhibitory peptide (Ip), the mobile domain of TnI, and TnT interactions with actin-Tm interface. The result is a movement of Tm permitting the actin-cross-bridge reaction. The extent of myofilament activation is governed by the number of cross-bridges reacting with the thin filament determined by the proportion of cTnC sites with bound Ca^{2+} related to the amounts of Ca^{2+} released and to the population of cross-bridges existing in a super-relaxed state (SRX) and a disordered relaxed state (DRX). As shown by the green arrow extending along the myofilaments, the extent of activation is also determined by the cooperative spread of activation from an active regulatory unit to near neighbors among the regulatory units. Cross-bridge interactions with thin filament promote this spread as do modifications in energies of interaction among neighboring thin filament proteins especially interactions at the ends of contiguous Tm strands. Critical regions of TnI differ between cTnI and ssTnI. The N-terminal extension is specific to cTnI. In homologous regions the cTnI Ip T143 is P111 in ssTnI, in the cTnI Sw Q155, A162 and E164 are R125, H132, V134 in ssTnI, and in the cTnI mobile domain cTnI H172 and K207 are N141 and M175 in ssTnI. Data from our studies indicate that myosin activators and inhibitors are affected by this difference, which affect activation and inhibition of tension. See text for further discussion.

Tables

Table 1. Ca^{2+} -activated tension parameters for skinned fibers of adult TG-ssTnl mice and NTG controls treated with 0.3 μM OM.

Skinned Fibers	Treatment	Max Tension (mN/mm ²)	pCa ₅₀	Hill Slope
NTG adult (n=5)	Control	33.50±3.07	5.73±0.03	5.65±0.30
NTG adult (n=5)	OM 0.3 μM	31.12±3.22	5.89±0.08 ^c	2.49±0.69 ^j
TG-ssTnl adult (n=5)	Control	26.62±2.75 ^a	5.94±0.05 ^d	3.12±0.36 ^k
TG-ssTnl adult (n=5)	OM 0.3 μM	26.66±4.71 ^b	6.07±0.07 ^{e,f,g}	1.96±0.21 ^{i,h}

^aP=0.0319, 95% CI of diff. [0.51 to 13.24] when compared to NTG adult Control; ^bP=0.0329, 95% CI of diff. [0.48 to 13.21] when compared to NTG adult Control; ^cP=0.0035, 95% CI of diff. [-0.27 to -0.05] when compared to NTG adult Control; ^dP=0.0002, 95% CI of diff. [-0.32 to -0.10] when compared to NTG adult Control; ^eP=0.0164, 95% CI of diff. [-0.24 to -0.02] when compared to TG-ssTnl adult Control; ^fP=0.001, 95% CI of diff. [-0.29 to -0.07] when compared to NTG adult 0.3 μM OM; ^gP<0.0001, 95% CI of diff. [-0.45 to -0.24] when compared to NTG adult Control; ^hP=0.0027, 95% CI of diff. [-1.94 to -0.39] when compared to TG-ssTnl adult Control; ⁱP<0.0001, 95% CI of diff. [-4.47 to -2.92] when compared to NTG adult Control; ^jP<0.0001, 95% CI of diff. [-3.94 to -2.39] when compared to NTG adult Control; ^kP<0.0001, 95% CI of diff. [-3.30 to -1.76] when compared to NTG adult Control. Data are presented as mean ± SD; 2-way ANOVA test followed with a Tukey's multiple comparison post-hoc test. NTG, non-transgenic; TG-ssTnl, transgenic slow skeletal Troponin I; OM, omecamtiv mecarbil.

Table 2. Ca²⁺-activated tension parameters for skinned fiber bundles of 7 and 14 day old NTG mice treated with 0.3 μM OM.

Skinned Fibers	Treatment	Max Tension (mN/mm ²)	pCa ₅₀	Hill Slope
NTG 7d (n=7)	Control	16.80±2.31	5.88±0.05	3.72±0.57
NTG 7d (n=7)	OM 0.3 μM	14.25±2.06 ^a	6.07±0.05 ^{e,f,g}	3.28±0.42 ⁱ
NTG 14d (n=6)	Control	22.65±3.27 ^b	5.80±0.03 ^h	5.29±1.08 ^j
NTG 14d (n=6)	OM 0.3 μM	21.83±3.01 ^{c,d}	5.86±0.06	3.21±0.72 ^k

^aP<0.0001, 95% CI of diff. [-12.52 to -4.29] when compared to NTG 14 day Control; ^bP=0.0035, 95% CI of diff. [-9.97 to -1.74] when compared to NTG 7 day Control; ^cP=0.013, 95% CI of diff. [-9.14 to -0.91] when compared to NTG 7 day Control; ^dP=0.0002, 95% CI of diff. [-11.69 to -3.47] when compared to NTG 7 day 0.3 μM OM; ^eP<0.0001, 95% CI of diff. [-0.26 to -0.12] when compared to NTG 7 day Control; ^fP<0.0001, 95% CI of diff. [0.20 to 0.34] when compared to NTG 14 day Control; ^gP<0.0001, 95% CI of diff. [0.14 to 0.28] when compared to NTG 14 0.3 μM OM; ^hP=0.0202, 95% CI of diff. [0.01 to 0.15] when compared to NTG 7 day Control; ⁱP=0.0003, 95% CI of diff. [0.89 to 3.13] when compared to NTG 14 day Control; ^jP=0.0037, 95% CI of diff. [0.46 to 2.69] when compared to NTG 7 day Control; ^kP=0.0003, 95% CI of diff. [-3.24 to -0.92] when compared to NTG 14 day Control. Data are presented as mean ± SD; 2-way ANOVA test followed with a Tukey's multiple comparison post-hoc test. NTG, non-transgenic; TG-ssTnl; transgenic slow skeletal Troponin I; OM, omecamtiv mecarbil.

Table 3. Ca^{2+} -activated tension parameters for skinned fiber bundles of adult TG-ssTnI mice and NTG controls treated with 0.3 μM Mava.

Skinned Fibers	Treatment	Max Tension (mN/mm ²)	pCa ₅₀	Hill Slope
NTG adult (n=5)	Control	35.38±4.93	5.68±0.08	4.05±0.86
NTG adult (n=5)	Mava 0.3 μM	19.89±3.92 ^a	5.55±0.07	4.96±0.95
TG-ssTnI adult (n=6)	Control	29.05.05±4.27 ^b	5.88±0.13 ^{e,f}	3.24±0.68 ^g
TG-ssTnI adult (n=6)	Mava 0.3 μM	14.19±4.41 ^{c,d}	5.73±0.12	3.46±0.96 ^h

^aP=0.0001, 95% CI of diff. [7.65 to 23.34] when compared to NTG adult Control; ^bP=0.0139, 95% CI of diff. [-16.68 to -1.65] when compared to NTG 0.3 μM Mava; ^cP<0.0001, 95% CI of diff. [13.68 to 28.71] when compared to NTG adult Control; ^dP<0.0001, 95% CI of dif. [7.70 to 22.03] when compared to TG-ssTnI adult Control; ^eP=0.029, 95% CI of diff. [-0.38 to -0.02] when compared to NTG adult control; ^fP=0.0005, 95% CI of diff. [-0.51 to -0.14] when compared to NTG 0.3 μM Mava; ^gP=0.0201, 95% CI of diff. [-3.19 to -0.23] when compared to NTG adult 0.3 μM Mava; ^hP=0.0465, 95% CI of diff. [-2.98 to -0.02] when compared to NTG adult 0.3 μM Mava. Data are presented as mean $\pm$ SD; 2-way ANOVA test followed with a Tukey's multiple comparison post-hoc test. NTG, non-transgenic; TG-ssTnI, transgenic slow skeletal Troponin I; Mava, mavacamten.

Table 4. Ca^{2+} -activated tension parameters for skinned fiber bundles of 7 day old TG-cTnT-R92Q mice and NTG controls treated with 0.3 μM Mava.

Skinned Fibers	Treatment	Max Tension (mN/mm ²)	pCa ₅₀	Hill Slope
NTG 7d (n=3)	Control	13.93±2.38	6.21±0.34	2.82±0.29
NTG 7d (n=3)	Mava 0.3 μM	6.87±1.31 ^a	6.07±0.29	3.54±0.31
TG-cTnT-R92Q 7d (n=7)	Control	15.04±3.52 ^b	6.08±0.23	3.33±0.45
TG-cTnT-R92Q 7d (n=7)	Mava 0.3 μM	7.88±1.66 ^{c,d}	5.97±0.25	3.26±0.49

^aP=0.0186, 95% CI of diff. [1.05 to 13.07] when compared to NTG 7 day Control; ^bP=0.0015, 95% CI of diff. [-13.24 to -3.09] when compared to NTG 7 day 0.3 μM Mava; ^cP=0.0004, 95% CI of diff. [3.23 to 11.09] when compared to TG-cTnT-R92Q 7 day Control; ^dP=0.0169, 95% CI of diff. [0.98 to 11.13] when compared to NTG 7 day Control. Data are presented as mean ± SD; 2-way ANOVA test followed with a Tukey's multiple comparison post-hoc test. NTG, non-transgenic; TG-cTnT-R92Q, transgenic cardiac troponin T with a point mutation at R92Q.

Table 5. Ca²⁺-activated tension parameters for skinned fiber bundles of 14 day old TG-cTnT-R92Q mice and NTG controls treated with 0.3 μ M Mava.

Skinned Fibers	Treatment	Max Tension (mN/mm ²)	pCa ₅₀	Hill Slope
NTG 14d (n=4)	Control	26.49 $\pm$ 4.20	5.73 $\pm$ 0.02	5.04 $\pm$ 0.69
NTG 14d (n=4)	Mava 0.3 μ M	13.30 $\pm$ 2.90 ^a	5.59 $\pm$ 0.04	5.62 $\pm$ 0.37 ^{i,j}
TG-cTnT-R92Q 14d (n=5)	Control	24.93 $\pm$ 4.83 ^b	5.94 $\pm$ 0.06 ^{e,f}	2.71 $\pm$ 0.34 ^k
TG-cTnT-R92Q 14d (n=5)	Mava 0.3 μ M	13.97 $\pm$ 2.97 ^{c,d}	5.75 $\pm$ 0.11 ^{g,h}	3.44 $\pm$ 0.57 ^l

^aP=0.0013, 95% CI of diff. [5.29 to 21.09] when compared to NTG 14 day Control; ^bP=0.0024, 95% CI of diff. [-19.13 to -4.14] when compared to NTG 14 day 0.3 μ M Mava; ^cP=0.0025, 95% CI of diff. [3.89 to 18.03] when compared to TG-cTnT-R92Q 14 day Control; ^dP=0.0013, 95% CI of diff. [5.02 to 20.01] when compared to NTG 14 day Control; ^eP=0.0022, 95% CI of diff. [-0.34 to -0.07] when compared to NTG 14 day Control; ^fP<0.0001, 95% CI of diff. [-0.48 to -0.22] when compared to NTG 14 day 0.3 μ M Mava; ^gP=0.0162, 95% CI of diff. [-0.29 to -0.03] when compared to NTG 14 day 0.3 μ M Mava; ^hP=0.0034, 95% CI of diff. [0.06 to 0.31] when compared to TG-cTnT-R92Q 14 day Control; ⁱP<0.0001, 95% CI of diff. [-3.91 to -1.92] when compared to TG-cTnT-R92Q 14 day Control; ^jP<0.0001, 95% CI of diff. [-3.17 to -1.18] when compared to TG-cTnT-R92Q 14 day 0.3 μ M Mava; ^kP<0.0001, 95% CI of diff. [-3.33 to -1.34] when compared to NTG 14 day Control; ^lP=0.0018, 95% CI of diff. [-2.59 to -0.60] when compared to NTG 14 day Control. Data are presented as mean $\pm$ SD; 2-way ANOVA test followed with a Tukey's multiple comparison post-hoc test. NTG, non-transgenic; TG-cTnT-R92Q, transgenic cardiac troponin T with a point mutation at R92Q.

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Figure 7

Figure 8